SLA: A Protein Implicated in Cell-Cell Adhesion and Cancer (G6503)

Target Name: SLA

NCBI ID: G6503

Content of Review Report on SLA Target / Biomarker

SLA

SLA: A Protein Implicated in Cell-Cell Adhesion and Cancer

SLA (Src-like-adapter (isoform a)) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell-cell adhesion and has been implicated in a number of diseases, including cancer. SLA has also been identified as a potential drug target and may be a biomarker for some diseases.

SLA was first identified in the late 1990s as a protein that was expressed in many tissues, including the brain, heart, and liver. It is a member of the Src family of proteins, which are known for their role in cell signaling. SLA is similar to other Src proteins, including src-like adapter (isoform b), which is also a key regulator of cell-cell adhesion.

One of the key functions of SLA is its role in cell-cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. SLA helps to regulate the formation of tight junctions, which are the weakest type of cell-cell adhesion, and also helps to maintain the integrity of adherens junctions, which are stronger types of cell-cell adhesion.

SLA has also been shown to play a role in a number of diseases, including cancer. For example, studies have shown that SLA is often overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This overexpression can lead to the formation of cell aggregates, which can be a hallmark of cancer.

In addition to its role in cell-cell adhesion, SLA has also been shown to play a role in a number of other processes in the body. For example, SLA has been shown to be involved in the regulation of cell signaling, as well as the development and maintenance of tissues and organs.

As a result of its role in these processes, SLA has been identified as a potential drug target for a number of diseases. For example, studies have shown that SLA can be targeted with small molecules, such as inhibitors of tyrosine kinase activity, which can inhibit the formation of cell aggregates and the formation of new tissues. In addition, SLA has also been shown to be involved in the regulation of cell signaling, which makes it a potential target for inhibitors of signaling pathways that are involved in cancer.

SLA has also been identified as a potential biomarker for some diseases. For example, studies have shown that SLA is often overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This overexpression can lead to the formation of cell aggregates, which can be a hallmark of cancer. Therefore, SLA levels may be a useful biomarker for some types of cancer.

In conclusion, SLA is a protein that is expressed in various tissues throughout the body and plays a role in cell-cell adhesion. It has also been implicated in a number of diseases, including cancer. As a result of its role in these processes, SLA has been identified as a potential drug target and may also be a useful biomarker for some types of cancer. Further research is needed to fully understand the role of SLA in these processes and to develop effective treatments for these diseases.

Protein Name: Src Like Adaptor

Functions: Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. Involved in the negative regulation of positive selection and mitosis of T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins

The "SLA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets